Myriad Genetics (MYGN) Q3 2026 Earnings Call Transcript

Myriad Genetics reported Q3 2026 revenue of $202.7 million, down 1% year over year, and adjusted EBITDA loss of $5.3 million; gross margin improved 130 basis points sequentially to 67.9%. It raised full-year revenue guidance midpoint by $5 million to $785 million and agreed to sell its Prenatal Health business to Labcorp for $210 million plus inventory, with closing expected in early 2027. Management expects the divestiture to lift gross margin by more than 500 basis points and revenue growth by over 100 basis points, while noting prenatal revenue could decline by about $5 million in Q4 and hereditary-cancer average revenue per test may face 1%–5% medium- to long-term annual headwinds.

Analysis

MYGN’s divestiture is a portfolio-quality improvement, not yet proof of a durable earnings inflection. The stated post-sale gross-margin uplift can be diluted by stranded overhead, separation costs and the pace of Ascend savings; revenue-growth optics also improve mechanically when a declining business exits. The key 2027 test is whether continuing-business growth converts to positive EBITDA without assuming a lasting HCT pricing recovery.

Near term, the 9% sequential HCT ASP rebound is encouraging but not conclusive: management attributes the pressure chiefly to denials, while still expecting 1–5% average annual ASP headwinds. That creates asymmetric execution risk—volume growth can coexist with weak revenue conversion. MRD’s interim sensitivity result is a clinical signal, not commercial validation; reimbursement timing and utilization remain the catalysts. Prolaris faces a separate substitution risk from guideline-supported blood-based testing and imaging.

LH may gain a business it can integrate into a broader operating platform, but the deal’s value to LH depends on retention, transition costs and whether acquired volume earns attractive returns; the disclosed sale multiple alone does not establish accretion. Other prenatal-testing providers could benefit if Labcorp’s transition disrupts customer continuity, though that is a watch item, not a base case.

Contrarian view: the cleaner MYGN story may be priced ahead of the evidence. The decisive 1–3 month signals are transaction/operating detail and continued HCT revenue conversion; the structural case runs 6–18 months through close, reimbursement decisions and cost actions. A reversal would be renewed HCT ASP deterioration, continued losses despite the mix shift, or delayed deal/reimbursement milestones.

Key Decisions for Investors

• MYGN: Avoid chasing the strategic-reset narrative before valuation and post-divestiture cost detail are available. Consider a small, staged long only after the deal remains on track and continuing-business results show revenue conversion alongside volume growth; reassess if HCT ASP resumes deterioration or EBITDA fails to improve through 2027.
• Track the deal close expected in early 2027, net proceeds allocation, stranded costs and Ascend targets. Treat management’s >500 bp gross-margin uplift as a hypothesis until reported results demonstrate it; debt reduction versus growth spending will change the equity-risk profile.
• Keep MRD as a catalyst watch, not a standalone earnings thesis: verify MolDX submission and breast-cancer coverage timing in 1H 2027, then evidence of paid utilization. Delays or weak early adoption would undermine the multiple-expansion case.
• LH: No standalone trade from this announcement. Monitor integration/retention and any disclosed transaction economics; the acquired business could strengthen its offering, but no quantified return or accretion case is established here.